THE CURE HEIST

Martin Shkreli raised the price of Daraprim from $13.50 to $750 overnight. Same pill, same molecule, same factory.

Turing Pharmaceuticals acquired Daraprim (pyrimethamine) rights in August 2015 and raised the list price by 5,455% the same month. The drug had been on the market for decades; the molecule, manufacturing process, and factory remained unchanged. Daraprim treats a parasitic infection that can be fatal for HIV patients and organ transplant recipients.

Shkreli bought the only copy of a Wu-Tang Clan album, "Once Upon a Time in Shaolin," for $2 million.

The album was produced as a single handcrafted copy, auctioned through Paddle8 in 2015. Shkreli won the auction for $2 million. The album was later seized by the US Department of Justice after Shkreli's securities fraud conviction and sold to PleasrDAO in 2021.

Shkreli was convicted of securities fraud. Told investors his fund had $35 million when it had less than $1,000. Claimed 35% return on an 18% loss.

The specific figures come from trial testimony and SEC filings related to MSMB Healthcare and Retrophin investor fraud. Shkreli misrepresented fund balances and returns to existing and prospective investors over multiple reporting periods.

Shkreli was sentenced to 7 years prison, paid $64 million in fines, and was banned from the pharmaceutical industry for life.

The original federal sentence included 7 years in prison and $7.36 million in forfeiture, with securities fraud penalties ultimately totaling approximately $64 million across related cases. The FTC imposed a separate lifetime ban from the pharmaceutical industry via antitrust action in January 2022 -- precedent-setting as an industry-exclusion remedy.

Health sector lobbying spending in 2024 exceeded $751 million -- the #1 lobbying sector in America for 10+ years running.

The figure aggregates quarterly LD-2 disclosures filed under the Lobbying Disclosure Act by pharmaceutical, insurance, hospital, and health services firms. The health sector has held the #1 lobbying rank continuously since the mid-2010s.

The top 3 PBMs control approximately 80% of all US prescription claims.

CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth) collectively control approximately 80% of prescription volume in the United States. All three are vertically integrated subsidiaries of major health conglomerates.

Employer-sponsored health insurance originated from the 1942 Stabilization Act's wartime wage freeze. The IRS codified the tax exemption in 1943.

The Stabilization Act of 1942 froze wages to prevent wartime inflation. Employers began offering health benefits as compensation because benefits were excluded from the wage cap. The IRS made employer-provided health insurance tax-exempt the following year, locking in the structure that persists today. "Temporary wartime fix" is historically accurate framing.

The largest pharmaceutical companies spent more on stock buybacks and dividends than on R&D from 2016 to 2020.

The US House Committee on Oversight and Reform's 2021 pharmaceutical pricing investigation found that 14 large pharma companies spent approximately $577 billion on stock buybacks and dividends, compared to approximately $521 billion on research and development, over the same five-year window. The industry's "prices fund innovation" defense is contradicted at the aggregate sector level.

AbbVie filed 247 patents on Humira (adalimumab) to extend exclusivity.

I-MAK's patent analysis identified 247 patent applications filed on Humira, with 132 granted. The strategy -- known as patent thicketing -- covered minor variations in formulation, delivery devices, dosing regimens, and manufacturing processes. The thicket delayed US biosimilar competition by approximately seven years relative to Europe.

Humira generated over $100 billion in cumulative revenue -- the best-selling drug in pharmaceutical history.

AbbVie's annual reports (10-K filings with the SEC) show cumulative Humira revenue surpassed $100 billion by approximately 2020 and exceeded $200 billion by 2023, including biosimilar-era sales. Humira holds the record as the best-selling prescription drug by cumulative revenue.

CVS owns Caremark (PBM) and Aetna (insurer). UnitedHealth owns OptumRx (PBM). Cigna owns Express Scripts (PBM). The same parent company negotiates the drug price, manages the benefit, and decides whether to cover it.

SEC 10-K filings document the vertical integration of the three largest health conglomerates. CVS Health acquired Aetna in 2018 for approximately $69 billion. Cigna acquired Express Scripts in 2018 for approximately $67 billion. UnitedHealth expanded OptumRx through its 2015 acquisition of Catamaran. In each case, the parent company now owns the insurer, the PBM, and (for CVS) the retail pharmacy -- creating a structural conflict of interest across every step of the prescription journey.

One Cigna doctor denied 121,000 claims in two months, averaging 1.2 seconds per claim.

ProPublica's investigation documented Cigna's internal "PXDX" claim-review system. Dr. Cheryl Dopke was named in the reporting as one of the medical directors handling high-volume denials. The system used an algorithm to flag claims for bulk denial, with medical directors approving the denials in rapid succession. Internal Cigna documents cited in the investigation support the 1.2-second-per-claim figure.

Health sector PAC donations to federal candidates in the 2024 cycle totaled $52 million, split roughly between both parties.

OpenSecrets PAC data shows health sector political action committees contributed approximately $52 million to federal candidates during the 2024 election cycle. Donations split roughly evenly between the two parties, with Republicans receiving slightly more than Democrats. The pattern of bipartisan donations is consistent across multiple cycles.

Joey's Humira prescription ($72,000 per year) was approved instantly; his $1,900 Bartonella blood test was denied.

Joey is a composite character used across the Body Tax story arc (EP01 through EP04), not a real patient. The specific figures are within documented ranges: Humira's 2024 US list price runs approximately $84,000 per year (Rheumatology Advisor, AbbVie formulary pricing). Comprehensive Bartonella testing panels (IgG, IgM, PCR) typically cost between $400 and $2,500 depending on lab and panel depth. The pattern -- expensive biologic approved easily while diagnostic testing is denied -- is documented across hundreds of real patient accounts in appeals literature.

Diagnostic tests generate no PBM rebate. Branded biologics generate large rebates. PBMs profit when the expensive drug is approved, not when the diagnostic test is run.

Rebate economics are well-documented in peer-reviewed health policy literature. Drugs on PBM formularies generate rebate revenue to the PBM and insurer. Laboratory tests do not. The financial incentive structure rewards approving branded biologic prescriptions and denying diagnostic workups -- regardless of clinical merit. This is a pattern-level claim about system economics, not a specific documented instance.

Total market index funds (Vanguard Total Market, S&P 500 index funds) hold UnitedHealth, CVS, Cigna, and AbbVie. Anyone with a 401k indexed to the broad market is invested in these companies.

Vanguard Total Stock Market Index Fund (VTSAX) and S&P 500 index fund holdings are publicly disclosed. UnitedHealth (UNH), CVS Health (CVS), Cigna (CI), and AbbVie (ABBV) are all S&P 500 components with meaningful index fund weight. Anyone holding a broad-market index fund in a US retirement account is invested in these companies proportional to the fund's weighting.

In 1923, the discoverers of insulin (Banting, Best, Collip) sold the insulin patent to the University of Toronto for $1 each.

The original patent assignment, dated January 1923, documents the sale of the insulin patent to the University of Toronto for $1 per inventor. Frederick Banting, Charles Best, and James Collip signed the assignment. The primary document remains housed in the University of Toronto Libraries' Banting Archive. The inventors filed the patent specifically to prevent anyone else from patenting it behind a paywall, then assigned it to the university to ensure the drug could be made widely available.

Frederick Banting said insulin "belongs to the world."

The quote is widely attributed to Banting in popular histories and biographical sources. However, no primary document in the University of Toronto Banting Archive containing this exact phrasing has been located. The script uses the qualifier "the story goes" to flag the attribution uncertainty. The sentiment is consistent with Banting's documented statements and actions, but the specific phrasing cannot be verified from primary sources.

Three companies (Eli Lilly, Novo Nordisk, Sanofi) control approximately 90% of the global insulin supply. Insulin list prices rose approximately 1,200% since 1999.

The insulin oligopoly is documented by the T1International pricing reports and the Senate Finance Committee's 2021 insulin pricing investigation. RAND Corporation's comparative pricing analysis found US insulin prices at roughly 10 times the average OECD price. The 1,200% figure references the move from approximately $21 per vial (1999) to approximately $275 per vial (peak pre-reform), based on manufacturer list prices at the three dominant suppliers.

Insulin costs approximately $3-6 per vial to manufacture. List prices reached $275 per vial.

BMJ Global Health published a 2018 analysis estimating insulin manufacturing cost at approximately $3-6 per vial, based on bulk active pharmaceutical ingredient pricing and fill-finish production costs. Manufacturer list prices reached approximately $275 per vial at peak, representing a markup of roughly 4,483% over manufacturing cost. Post-Inflation Reduction Act insulin caps ($35 per month for Medicare beneficiaries) reduced what some patients pay, but did not change list price or cash price at most pharmacies.

Alec Smith, 26, died rationing insulin he could not afford.

Alec Raeshawn Smith, a resident of Minnesota, died on June 27, 2017, of diabetic ketoacidosis. After timing out of his mother's insurance at age 26, Smith rationed his insulin to save money. The case was documented by T1International, reported by multiple major news outlets, and cited in Senate Finance Committee hearing testimony. Minnesota subsequently passed the Alec Smith Insulin Affordability Act in 2020 in response to his death.

Mark Cuban's Cost Plus Drugs charges cost + 15% + $3 pharmacy fee + shipping -- bypassing the PBM. Covers over 2,000 medications.

Cost Plus Drug Company's pricing model is posted publicly on costplusdrugs.com. Each drug's true manufacturer cost, the 15% markup, the $3 pharmacy labor fee, and shipping costs are visible per-drug. The company launched its direct-to-consumer model in January 2022. As of 2024, Cost Plus offers over 2,000 medications, primarily generics and off-patent drugs. The episode's spoken handle also references Costco Pharmacy (no membership required for prescriptions under federal law), LillyDirect (manufacturer-direct insulin and GLP-1s), NovoCare (manufacturer-direct insulin and GLP-1s), and GoodRx (pharmacy price comparison engine).